Nanotechnology Now

Our NanoNews Digest Sponsors







Heifer International

Wikipedia Affiliate Button


Home > Press > Nanoparticle Breast Cancer Drug O.K.D by FDA

Abstract:
"The approval means that women with metastatic breast cancer no longer need to endure the toxicities associated with solvents and will no longer need steroid premedication when they receive this albumin-bound form of paclitaxel."

Nanoparticle Breast Cancer Drug O.K.D by Food and Drug Administration

March 10, 2005

Research at Northwestern University Feinberg School of Medicine played a significant role in Food and Drug Administration approval of AbraxaneTM (paclitaxel protein-bound particles for injectable suspension), indicated for the treatment of metastatic breast cancer.

“The approval means that women with metastatic breast cancer no longer need to endure the toxicities associated with solvents and will no longer need steroid premedication when they receive this albumin-bound form of paclitaxel,” said principal clinical study investigator William J. Gradishar, M.D., associate professor of medicine, division of hematology/oncology at Feinberg and co-director, Lynn Sage Breast Cancer Program at Northwestern Memorial Hospital.

Gradishar is also a breast cancer researcher at The Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

“In our research, participants who no longer responded to some of the more common treatments showed improvement with Abraxane and experienced less-severe side effects that made treatment more tolerable,” Gradishar said.

Abraxane is engineered using a proprietary process (protein-bound nanoparticle technology) to create tiny particles (nanoparticles 100th the size of a red blood cell) in which the active chemotherapeutic drug, paclitaxel, is bound to a naturally occurring protein called albumin.

By using this nanotechnology, the active component (paclitaxel) can be delivered into the body at a 50 percent higher dose over 30 minutes.

This contrasts with Taxol, in which paclitaxel is dissolved in a toxic solvent, which requires pre-medication with steroids and antihistamines to avoid hypersensitivity reactions and must be given in infusions for up to three hours.

Because Abraxane is solvent-free, solvent-related toxicities are eliminated and premedication is not required.

In the clinical studies, the response rate for all participants treated with Abraxane was almost twice that of participants receiving the solvent-based paclitaxel injection. Without toxic solvents, Abraxane could be given at higher doses than Taxol, which may account, in part, for the increased anti-tumor activity.

In addition, albumin is a protein that normally transports nutrients to cells and has been shown to accumulate in rapidly growing tumors. Therefore, Abraxane’s increased effectiveness may also be due to preferential delivery of albumin-bound paclitaxel to cancer cells.

Abraxane was developed by American Bioscience and will be marketed by Abraxis Oncology, a division of American Pharmaceutical Partners.



Media Contact:
Elizabeth Crown
312-503-8928
e-crown@northwestern.edu

Copyright © Northwestern University

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Possible Futures

Space Solar Power: Key to a Livable Planet Earth June 10th, 2013

Global Nanotechnology Drug Delivery Market 2012-2016 June 10th, 2013

Nanorobot tetanus treatment animation June 9th, 2013

New horizons to drive the future of Medicine: European Technology Platform on Nanomedicine intends to lead the domain June 8th, 2013

Nanomedicine

Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013

Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013

Production of Polyaniline Biosensors Modified with Conductive Polymer Composites June 18th, 2013

European Technology Platform for Nanomedicine and Nanomed2020 European Consortium Launch the Nanomedicine Award June 17th, 2013

Announcements

Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013

Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013

New Method to Synthesize Zinc Oxide Nanoparticles with High Catalytic Activity June 18th, 2013

Production of Polyaniline Biosensors Modified with Conductive Polymer Composites June 18th, 2013

NanoNews-Digest
The latest news from around the world, FREE







  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More












ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project








abbigliamento uomo
Computer Accessories
© Copyright 1999-2013 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE